Search academic texts

Information × Registration Number 0214U006739, 0112U001373 , R & D reports Title Investigation of the mechanisms of influence on hemostasis in vitro and in vivo concentrates clotting factors and their therapeutic effect in patients with hemophilia and inhibitors popup.stage_title Head Loginsky Volodymyr Eustakhovych, Доктор медичних наук Registration Date 12-02-2014 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 Object of study were 24 patients with hemophilia A and B, ages 1 to 75 years who were hospitalized in a clinic or outpatient department of SI " Institute of Blood Pathology and Transfusion Medicine, Academy of Medical Sciences of Ukraine" Aim. To develop methods for predicting the severity of hemorrhagic manifestations and determine efficacy concentrates of factor VIII, recombinant activated factor VII, coagulation factors II, VII, IX, X , and their combination in hemophilia A patients with inhibitors based on coagulation test in vitro and in vivo. Methods. Clinical and laboratory studies included clinical examination , coagulation tests, hematology, biochemical research. It used Micros 60 hematology analyzer T number 81473 , biochemical analyzer Point +180, SR 1907.1674, coagulometer Helena- C4 C4- number 2489. Results. APTT extent shortens greater after adding activated recombinant factor VII (rFVIIa) than after adding activated prothrombin complex ( aPCC ). Although both drugs do not normalize the studied parameters after adding to the plasma of hemophilia patients with inhibitors ex vivo / in vitro in recommended doses. Changes in FVIII or FIX inhibitor titer during therapy with APCC was individual, and does not depend on the initial titer inhibitor, dose and type of treatment (prophylaxis , " on demand "). The majority of hemophilia A subjects did not change inhibitor titer classification throughout the study. Conclusion. APTT is informative and accessible method for monitoring the haemostatic effect of bypassing agents in patients with hemophilia with inhibitors ex vivo / in vitro. Product Description popup.authors Дзісь Р.П. Красівська В.В. Стасишин О.В. Тушницький О.М. popup.nrat_date 2020-04-02 Close